Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders based on genetic insights.
Secondary Market Price
Secondary Market Price
How Praxis Measures Up
To help you manage your Praxis equity, Prospect has run the company through our machine learning model.
Prospect Rating
Exit Risk
Funding Stage
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Praxis's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Praxis Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Praxis's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly those involving an imbalance of neuronal excitation and inhibition. The company translates genetic insights, primarily from genetic epilepsies, into potential treatments and currently has four clinical-stage assets in its pipeline. Its present activities include conducting ongoing clinical trials, such as the RESILIENCE STUDIES and POWER1. The company was founded to apply theoretical knowledge from genetics in a practical way to drug development for CNS disorders. Steve Petrou is noted as a Co-Founder and the company's Chief Scientific Officer.
Praxis has stated a mission to develop and deliver treatments for CNS disorders, with a focus on expanding its portfolio of precision therapies. The company's strategy involves advancing its existing clinical-stage and early-stage programs through a development process it describes as patient-guided and rigorous. Current activities that support these plans include the continuation of its clinical trials and the operation of an expanded access policy for its investigational medicines.
- Eventide Asset Management
- Vida Ventures
- Novo Holdings
- Blackstone Life Sciences
- OCV Partners
- Avoro Capital Advisors
- Surveyor Capital
- Point72
- Cormorant Asset Management
- Qatar Investment Authority
- Irving Investors
- Adage Capital Management
- Verition Fund Management
- Ample Plus Fund
- Co-Founder, [Executive Title] Kiran Reddy, M.D.
- Co-Founder, [Executive Title] David Goldstein, Ph.D.
- Co-Founder, [Executive Title] Steven (Steve) Petrou, Ph.D.
- Co-Founder, [Executive Title] Ari Brettman, M.D.
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Praxis worth joining?
Deciding whether to join any startup, including Praxis, depends on your personal career goals and risk tolerance. You should thoroughly research the company's leadership, market position, and growth potential before making a decision.
What should I do with my Praxis stock?
Managing stock from a private company like Praxis involves complex financial and tax planning. Using a platform like Prospect can help you model different scenarios and make informed decisions about your equity.
Can you sell Praxis stock?
As a private company, Praxis stock is not traded on public exchanges, but it can sometimes be sold through secondary markets or tender offers. Tools like Prospect can provide guidance and resources for navigating private stock sales.
How can I find the value of my Praxis stock?
The value of private company stock is typically determined by its most recent 409A valuation, which you can request from the company. Platforms like Prospect can also help you forecast the potential future value of your equity based on various growth scenarios.
What is Praxis's equity worth?
The exact worth of Praxis's equity is not public information and is based on the company's private 409A valuation. This valuation can change with new funding rounds and overall company performance.
What is Praxis's stock ticker symbol?
Since Praxis is a private company and not publicly traded, it does not have a stock ticker symbol. Ticker symbols are only assigned when a company lists its shares on a public stock exchange.
Can I buy or sell Praxis stock?
Selling stock in a private company like Praxis is sometimes possible through secondary marketplaces, though it is often subject to company restrictions. Buying shares is typically limited to accredited investors and is less common for employees or the general public before an IPO.
What is the criteria to buy or invest in Praxis stock?
Investing in a private, pre-IPO company like Praxis is generally restricted to accredited investors who meet specific financial criteria set by securities regulators. These opportunities are not typically available to the general public.
